The FINANCIAL -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced on November 2 a number of changes to its Executive Committee. In a message to employees, Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, detailed the new appointments and his new management team.
In order to manage the Group’s new business activities beyond pharmaceuticals, Hanspeter SPEK is appointed President, Global Operations. He was previously Executive Vice President, Pharmaceutical Operations.
Given the strategic importance of the Transforming R&D program, Marc CLUZEL is appointed Executive Vice President, Research & Development. He was previously Senior Vice President, Research & Development.
Finally, due to the essential role of Sanofi Pasteur, the vaccines worldwide leader, Wayne PISANO, Senior Vice President, Vaccines, joins the Group’s Executive Committee.
As from today, the Executive Committee, chaired by Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, meets twice a month and comprises the following members :
- Marc CLUZEL, Executive Vice President, Research & Development
- Jérôme CONTAMINE, Executive Vice President, Chief Financial Officer
- Laurence DEBROUX, Senior Vice President, Chief Strategic Officer
- Karen LINEHAN, Senior Vice President, Legal Affairs and General Counsel
- Philippe LUSCAN, Senior Vice President, Industrial Affairs
- Wayne PISANO, Senior Vice President, Vaccines
- Roberto PUCCI, Senior Vice President, Human Resources
- Hanspeter SPEK, President, Global Operations.
Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis declared: “ I am extremely pleased to work with this international team who gathers competence, energy and experience to transform sanofi-aventis into a global diversified healthcare leader”.
Related Stories
